Literature DB >> 27007227

Regulatory T Cells in Chronic Graft-Versus-Host Disease After Extracorporeal Photopheresis: Correlation With Skin and Global Organ Responses, and Ability to Taper Steroids.

Helen A Denney1, Robert J Whittle, Jennifer Lai, Richard M Jacques, Peter C Taylor.   

Abstract

BACKGROUND: Induction of immune tolerance by an increase in regulatory T (Treg) cells after extracorporeal photopheresis (ECP) is thought to contribute to how ECP exerts its therapeutic effect in patients with chronic graft-versus-host disease (cGvHD). We investigated whether percentages and absolute counts of Treg cells changed post-ECP, and examined correlation with response.
METHODS: Absolute counts and % of CD4+ T cells and Treg cells (CD4 + CD25 + FOXP3 + CD127dim/-) were evaluated using flow cytometry in 32 patients with cGvHD treated by ECP for a minimum of 3 months, and up to 12 months. CD4+ or Treg cells at baseline to 12 months post-ECP were compared with changes in skin disease scores or global organ involvement, or the ability to taper steroids, at 14, 28, and 56 weeks.
RESULTS: Regulatory T cells % increased significantly above any overall changes in CD4+ % at 6, 9, and 12 months post-ECP. There was no statistically significant association between Treg cells and skin or steroid response, whereas a larger increase in CD4+ count from baseline to 1 to 3 months corresponded to increased odds of being able to reduce steroid dose by 50% or greater at 14 weeks. Skin and global organ responders at 28 weeks had higher median Treg cell counts 3 months post-ECP than nonresponders, as did steroid responders at 56 weeks who were 12 months post-ECP.
CONCLUSIONS: Regulatory T cell counts and % varied greatly among cGvHD patients, and the increase post-ECP was not significant until 6 months. No clear correlation was found between Treg cells and clinical improvement, suggesting that increases in Treg cell numbers and/or proportions are not driving the mechanism leading to a response after ECP.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 27007227     DOI: 10.1097/TP.0000000000001165

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  9 in total

Review 1.  Extracorporeal Photopheresis: A Case of Immunotherapy Ahead of Its Time.

Authors:  Pablo Augusto Vieyra-Garcia; Peter Wolf
Journal:  Transfus Med Hemother       Date:  2020-05-27       Impact factor: 3.747

Review 2.  Photopheresis: Advances and Use in Systemic Sclerosis.

Authors:  Xiaolong Alan Zhou; Jaehyuk Choi
Journal:  Curr Rheumatol Rep       Date:  2017-06       Impact factor: 4.592

3.  Should we use extracorporeal photopheresis more often? Evidence from graft-versus-host disease patients monitored with Treg as a biomarker.

Authors:  Sérgio Machado Lopes; Susana Roncon; Ana Catarina Pinho; Filipa Bordalo; Luís Antunes; Fernando Campilho; António Campos; Altamiro Costa-Pereira
Journal:  Future Sci OA       Date:  2020-08-10

Review 4.  Recent advances into the role of pattern recognition receptors in transplantation.

Authors:  Hrishikesh S Kulkarni; Davide Scozzi; Andrew E Gelman
Journal:  Cell Immunol       Date:  2020-03-07       Impact factor: 4.868

Review 5.  Cutaneous Graft-Versus-Host Disease: Diagnosis and Treatment.

Authors:  Karla Strong Rodrigues; Carla Oliveira-Ribeiro; Silvia de Abreu Fiuza Gomes; Robert Knobler
Journal:  Am J Clin Dermatol       Date:  2018-02       Impact factor: 7.403

Review 6.  Advances in the Use of Regulatory T-Cells for the Prevention and Therapy of Graft-vs.-Host Disease.

Authors:  Reshma Ramlal; Gerhard C Hildebrandt
Journal:  Biomedicines       Date:  2017-05-16

7.  Photopheresis efficacy in the treatment of rheumatoid arthritis: a pre-clinical proof of concept.

Authors:  Céline Coppard; Francis Bonnefoy; Dalil Hannani; Françoise Gabert; Olivier Manches; Joel Plumas; Sylvain Perruche; Laurence Chaperot
Journal:  J Transl Med       Date:  2019-09-18       Impact factor: 5.531

Review 8.  Extracorporeal Photopheresis (ECP) and the Potential of Novel Biomarkers in Optimizing Management of Acute and Chronic Graft vs. Host Disease (GvHD).

Authors:  Matthew Mankarious; Nick C Matthews; John A Snowden; Arun Alfred
Journal:  Front Immunol       Date:  2020-01-31       Impact factor: 7.561

Review 9.  Monogenic Immune Diseases Provide Insights Into the Mechanisms and Treatment of Chronic Graft-Versus-Host Disease.

Authors:  Jacob Rozmus
Journal:  Front Immunol       Date:  2021-02-04       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.